QOP
CRVS icon

Quinn Opportunity Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Quinn Opportunity Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,327
Closed -$71K – 372
2025
Q1 		$71K Hold
22,327
– – ﹤0.01% 375
2024
Q4 		$119K Hold
22,327
– – 0.01% 351
2024
Q3 		$118K Hold
22,327
– – 0.01% 264
2024
Q2 		$40.6K Hold
22,327
– – ﹤0.01% 271
2024
Q1 		$39.7K Buy
+22,327
New +$46.6K ﹤0.01% 247

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quinn Opportunity Partners's CRVS Position: Q2 2025 in Review

Quinn Opportunity Partners sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 22,327 shares — an estimated $71K sold.

Quinn Opportunity Partners first reported a position in CRVS in Q1 2024 and held it in 5 quarters. The position peaked at $119K in Q4 2024. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Quinn Opportunity Partners reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Quinn Opportunity Partners sold 22,327 Corvus Pharmaceuticals shares in Q2 2025, an estimated $71K.
  • Quinn Opportunity Partners first reported a position in Corvus Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Quinn Opportunity Partners's Corvus Pharmaceuticals position peaked at $119K in Q4 2024.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Quinn Opportunity Partners's 13F filing for Q2 2025, filed 8 Aug 2025.